Sciensus - Rare Disease Services’ Post

🌟 Medaxes joins the Critical Medicines Alliance! 🌟 Medaxes is proud to be part of the #CriticalMedicinesAlliance (CMA) and its commitment to a future where all patients have sustainable access to the medicines they need. Our involvement in the CMA stems from our strong beliefs that constructive collaboration between National and European Authorities and stakeholders is crucial to safeguard sustainable access to baseline medicines for all Belgian patients. Medaxes is committed to ensure the optimal synergy between the initiatives of the Belgian Working Group For The Availability Of Medicines and the goals that are identified by the Critical Medicines Alliance. #LevellingUp #TogetherforHealth #Medaxes #baselinemedicines #EU2024BE Medicines for Europe Adrian van den Hoven European Commission

Catch up on the key insights from Session 2 at #ISPOR_Saudi24! Watch the promo of the speakers discussing “Contracting and Market Access Strategies for Orphan Drugs”

Catch up on the key insights from Session 2 at #ISPOR_Saudi24! Watch the promo of the speakers discussing “Contracting and Market Access Strategies for Orphan Drugs” 🤩

In a joint call, 12 public health organizations from the European Union urge prospective Members of the European Parliament (MEPs) to safeguard access to affordable medicines. Access to medical products is increasingly under pressure in the EU. New medicines are often excessively expensive. As a result, they become unaffordable for patients who pay out of pocket and when reimbursed, the high costs place a heavy burden on countries' health budgets. The next European Parliament, elected in June, should promote the necessary measures and safeguards to ensure fair pricing and access for all. In addition to Wemos, the call has been signed by: Health Action International (Netherlands), Pharmaceutical Accountability Foundation (Netherlands), Salud por Derecho - Right to Health Foundation (Spain), Asociación Acceso Justo al Medicamento (Spain), Access to Medicines Ireland, EKPIZO (Greece), the Romanian Association Against AIDS, Association of European Cancer Leagues (EU), European AIDS Treatment Group (EU), the European Fair Pricing Network (EU), and UAEM (Universities Allied for Essential Medicines) Europe (EU). Read the joint call: https://lnkd.in/e8KxZBca #UseYourVote #EUelections2024 #EP2024 #accesstomedicines

Serious challenges face some EU/EEA countries when they are securing access to vital TB medicines, in particular for drug resistant TB. That’s why we have joined forces with the Federal Ministry of Health of Germany to bring country representatives together in Berlin on 4 & 5 June to find a way forward. Unlike many low-and middle-income countries of the WHO European Region, Central and Western European countries report encountering critical product gaps, unreliable supplies and eye-wateringly high prices for key medicines. I believe we will find a way to solve this problem and next week’s meeting represents a step forwards. More info about the meeting 👉 https://bit.ly/4e1Wmjy

Let´s learn more about #Nasalpolyps

🚨 𝐓𝐨𝐝𝐚𝐲, 𝟏𝟐 𝐉𝐮𝐧𝐞 𝟐𝟎𝟐𝟒, 𝐄𝐅𝐏𝐈𝐀 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐭𝐡𝐫𝐞𝐞 𝐫𝐞𝐩𝐨𝐫𝐭𝐬 𝐰𝐡𝐞𝐫𝐞 𝐢𝐭 𝐢𝐬 𝐬𝐡𝐨𝐰𝐧 𝐭𝐡𝐚𝐭 𝐝𝐢𝐬𝐩𝐚𝐫𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐭𝐢𝐦𝐞 𝐢𝐭 𝐭𝐚𝐤𝐞𝐬 𝐟𝐨𝐫 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐭𝐨 𝐚𝐜𝐜𝐞𝐬𝐬 𝐧𝐞𝐰 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐩𝐞𝐫𝐬𝐢𝐬𝐭. Across the region, the average time to patient access is 531 days. Ranging from 126 days in Germany to 889 days in my country, Romania. The primary causes include slow regulatory processes, late market access assessments, duplicative evidence requirements, and reimbursement delays. Additionally, local formulary decisions exacerbate these issues. These delays highlight the broader inequities in patient access to new medicines across Europe, with Central and Eastern European countries, including Romania, being one of the most affected. https://lnkd.in/ecwD8D9E #EFPIA #MedicineAccess

The Critical Medicines Alliance launch is anticipated later this week, and we’re proud to be part of it.     Did you know that if we line up the packs of essential medicines supplied by Viatris in the EU, they will stretch across the land borders of the EU? 141 million packs of critical medicines, to be more precise.     Driven by our mission to empower people worldwide to live healthier at every stage of life, access to medicines is not just an initiative for us. It is at the core of our business model. We are Access at Scale–supplying medicines to approximately 1 billion patients globally.     Our vision in Europe is ambitious: to achieve universal access to critical medicines, so that patients in every country have access to the medicines they need without barriers.    This vision motivates our continued commitment to the Critical Medicines Alliance and collaborative efforts across the healthcare ecosystem.    #AccessAtScale; #ViatrisEurope; #CriticalMedicinesAlliance 

PN Update: Human medicines European public assessment report (EPAR): Viekirax, ombitasvir,paritaprevir,ritonavir, Date of authorisation: 14/01/2015, Revision: 28, Status: Withdrawn (authorisation)

PN Update: Human medicines European public assessment report (EPAR): Nyxthracis (previously Obiltoxaximab SFL), obiltoxaximab, Date of authorisation: 18/11/2020, Revision: 3, Status: Withdrawn (authorisation)